|
Mar 5
|
Shattuck Labs Full Year 2023 Earnings: Beats Expectations
|
|
Mar 4
|
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
|
|
Dec 21
|
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
|
|
Dec 21
|
We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
|
|
Dec 5
|
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation...
|
|
Nov 6
|
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
|
|
Nov 2
|
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 An...
|